The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.
about
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysisRNase MRP and diseaseFunctional autoantibodies in systemic sclerosis pathogenesis.Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry.Raynaud's phenomenon, inflammatory arthritis, and weight loss: pay attention to the man behind the curtain.Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).Antinuclear antibody-negative systemic sclerosis.Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresSuccessful treatment of long-term severe progressive interstitial pneumonia with low-dose corticosteroid and azathioprine in a patient with diffuse systemic sclerosisClinical and serological features of systemic sclerosis in a Chinese cohort.Systemic sclerosis with hemoptysis and a huge lung cavity.The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis.Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Case of diffuse cutaneous systemic sclerosis with anti-Ku and anti-centromere antibodies.Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil.A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis.Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis.High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies.Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.Possible association of elevated serum collagen type IV level with skin sclerosis in systemic sclerosis.Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort.Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc.Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement.Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome.Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.Reply: To PMID 25512203.Rapidly progressive systemic sclerosis associated with breast carcinoma: report of a case with anti-RNA polymerase III antibody.
P2860
Q27000819-C0606118-D4A4-45C3-94DE-7EC7ED77F4FBQ30048481-8CD22CB9-926E-4A0A-9953-8BA4637B3C14Q33360501-37DFB76F-1291-49AA-9BC0-F5B816E2053BQ34107962-BD24FEFF-9DE5-49D6-8570-E3522ECC650CQ34128276-B9DA7F14-9453-43E7-B298-22C1656BC391Q34128485-570DB0B6-9375-41D2-A5E3-7D153F21F52AQ34661961-EC9E7148-A5F6-4681-ADA7-4FBF7D61243BQ35532333-4422D8C0-7EBA-406A-A382-59B4F6F5EBE3Q35649228-EDAFFE8E-1379-44C5-BFFD-E2FAB1C3BB30Q35661256-8D959B98-33C4-4CAE-B17C-8801526CAB8DQ35840816-32E677E0-896B-41E2-B047-D8EA78138862Q36311219-7A108F13-EED0-458D-9B49-6CE8F8ADEF22Q37073717-D36EEAF2-D317-4913-A694-57658C3A9FDAQ37694379-F4B357F3-B070-46D5-BF0F-7F0D5C2CE1CCQ38730172-BB802E67-32FC-4094-AD01-4F47E3D3DA1FQ38771824-A8AA736A-A5B3-4E3A-9ADF-6C4D8418C3BCQ39153772-4D300BD2-032B-4AC4-8687-EB26BD7BE7B3Q40018267-58607918-7D96-47DD-A5A3-C6CEA0C46572Q40022358-1694923F-9313-458A-ADC4-78A616DF1F09Q40063705-1CF86E22-82EC-45F9-9D0C-6990EAD05E42Q40151676-48E21304-8358-4E87-842F-EA2D1B06A031Q40241820-16C19C8C-B9CC-4D36-8F18-27E1562C05C7Q40296383-CAD65E92-A7E4-4E25-81AF-0A9D054E6EF1Q40400741-F505E8F3-D943-4928-B917-1A63FE0528FDQ40502385-20FDEC2D-00C8-4B2D-802A-623DB1551A3CQ40656308-A1CD42CD-FD10-427F-ABD6-6BC8BE7BE459Q47634882-422D2979-9F37-4C03-9FFE-03BEC0998D5FQ50774790-55AE89FA-D8A6-4776-B47A-B7FF69D1E209Q52597638-1D72B670-A27B-4EC8-8315-BC10E2D11010Q53388034-26272622-B69F-4BAA-B234-A8BE651FCE06Q53645962-03B3E10F-52DC-4F56-A4F5-7F52B224284CQ54271316-B25E1253-D093-42E4-AAA5-906530AB67D9Q54561829-2FDEC1FF-E866-4040-B7AB-22B4333CC9D5
P2860
The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The clinical relevance of seru ...... ients with systemic sclerosis.
@ast
The clinical relevance of seru ...... ients with systemic sclerosis.
@en
type
label
The clinical relevance of seru ...... ients with systemic sclerosis.
@ast
The clinical relevance of seru ...... ients with systemic sclerosis.
@en
prefLabel
The clinical relevance of seru ...... ients with systemic sclerosis.
@ast
The clinical relevance of seru ...... ients with systemic sclerosis.
@en
P2093
P2860
P50
P1476
The clinical relevance of seru ...... tients with systemic sclerosis
@en
P2093
C Nishijima
I Hayakawa
K Takehara
M Fujimoto
Y Hamaguchi
P2860
P304
P356
10.1111/J.1365-2133.2007.08392.X
P407
P577
2008-01-17T00:00:00Z